The biggest opportunities are emerging where long-standing PBM economics collide with AI, automation, regulatory pressure, and the shift toward high-cost specialty drugs. Rather than one giant disruption, it's a series of targeted attacks on parts of the value chain.
Here are the areas I think have the most potential over the next 3–7 years:
| Opportunity | Why it matters | Level of disruption |
|---|
| AI prior authorization | Reduces administrative burden and turnaround times | High |
| Specialty pharmacy workflow automation | Labor-intensive processes remain largely manual | High |
| Drug pricing transparency | Employers increasingly demand visibility | Medium-High |
| Biosimilar optimization | Billions in potential savings remain unrealized | High |
| Patient adherence platforms | Specialty medications only work if patients stay on therapy | Medium |
| Clinical decision support | Matching patients to optimal therapies earlier | High |
| Alternative PBM models | Employers are questioning traditional spread pricing | Very High |
1. Prior Authorization Automation
Prior authorization is still one of healthcare's biggest administrative pain points.
Opportunities include:
- AI-assisted clinical review
- Automated document extraction from EHRs
- Real-time eligibility verification
- Predictive approval scoring
- Electronic appeals generation
Savings come from reducing both provider burden and payer administrative costs.
2. Specialty Pharmacy Operating Systems
Specialty pharmacies coordinate:
- benefits investigation
- prior authorization
- financial assistance
- refill management
- nursing
- shipping
- adherence
Many still use fragmented systems with manual work.
There's room for:
- AI copilots for pharmacy technicians
- automated patient outreach
- workflow orchestration
- intelligent work queues
- integrated CRM + clinical platforms
This is a large operational efficiency opportunity.
3. Intelligent Patient Navigation
Specialty drugs often cost tens of thousands of dollars annually.
Patients frequently struggle with:
- insurance approval
- copay assistance
- scheduling
- education
- refill coordination
AI agents can:
- answer routine questions
- coordinate benefits
- schedule deliveries
- monitor adherence
- escalate clinical issues when needed
This improves both patient experience and therapy persistence.
4. Biosimilars
Many health systems still have low biosimilar adoption despite significant cost savings.
Technology can help:
- identify eligible patients
- estimate savings
- automate provider outreach
- optimize formulary placement
- monitor switching outcomes
This is likely to remain a major opportunity as more biologics lose exclusivity.
5. PBM Transparency Platforms
Large employers increasingly want to know:
- What drugs are driving spend?
- Which rebates are retained?
- Which specialty drugs have alternatives?
- Are patients receiving the lowest net-cost therapy?
Opportunities include analytics platforms that:
- audit PBM contracts
- benchmark pricing
- model formulary changes
- detect waste
- identify optimization opportunities
6. AI for Clinical Pharmacists
Clinical pharmacists spend substantial time reviewing cases.
AI can assist by:
- summarizing patient histories
- identifying guideline-supported therapies
- highlighting drug interactions
- drafting documentation
- surfacing relevant literature
The pharmacist remains the decision-maker, while AI reduces documentation time.
7. Rare Disease Care Coordination
Gene therapies and rare disease treatments often involve:
- multiple specialists
- manufacturer hubs
- infusion centers
- financial assistance
- travel coordination
This is a highly fragmented process.
Platforms that coordinate these activities can reduce delays and improve patient experience.
8. Predictive Specialty Analytics
Instead of reacting after costs occur, organizations want to predict them.
Potential applications include:
- forecasting specialty spend
- identifying members likely to initiate biologic therapy
- predicting therapy discontinuation
- anticipating adherence challenges
- estimating future cost trends
These insights can support earlier interventions and budget planning.
9. Alternative PBMs
This may represent the most significant business-model disruption.
Market trends include:
- pass-through pricing
- transparent rebate handling
- employer-owned formularies
- cost-plus pharmacy models
- independent specialty pharmacy networks
The market is moving away from opaque pricing toward measurable value and transparency.
10. AI Revenue Cycle for Specialty Pharmacy
Specialty pharmacies face complex reimbursement processes.
AI can support:
- benefits verification
- coding assistance
- claims scrubbing
- denial prediction
- appeal drafting
- reimbursement optimization
Even modest improvements in reimbursement accuracy can have a meaningful financial impact.
Areas that remain underserved
Several problems are still relatively under-addressed:
- Manufacturer hub optimization: Pharmaceutical companies spend heavily on patient support services, but many hub operations remain fragmented and manual.
- Provider-PBM communication: Information often flows through faxes, phone calls, and disconnected portals, creating delays.
- Unified specialty data platforms: Clinical, pharmacy, laboratory, claims, and financial data are frequently siloed, limiting comprehensive decision-making.
- Copay assistance optimization: Patients and providers often struggle to identify and coordinate available assistance programs efficiently.
Where I would focus if building a company today
If I were starting a venture in this space, I'd prioritize AI infrastructure that integrates across stakeholders rather than another standalone application. A compelling direction would be an AI-powered operating layer for specialty pharmacy that combines prior authorization automation, benefits investigation, technician copilots, patient communication, and predictive work prioritization. These capabilities directly target administrative costs while improving turnaround times and patient experience.
Another attractive area is serving self-insured employers with analytics that explain specialty drug spending, compare PBM performance, identify biosimilar opportunities, and recommend lower-net-cost strategies. As specialty medications account for an increasing share of pharmacy spend, buyers are demanding better visibility and measurable outcomes.
Overall, the strongest opportunities are those that reduce administrative friction while improving transparency and clinical coordination. Solutions that can demonstrate both operational savings and better patient outcomes are likely to see the strongest adoption, particularly as employers, payers, providers, and regulators continue to push for greater efficiency and accountability.